Skip to main content

Security report for biogen.co.nz

Biogen NZ Biopharma Limited · Healthcare · New Zealand

Low risk. 2 critical or high findings in Email security and SSL/TLS.

Security score

78/100

Risk levelLow

0–100, higher is better. How it is calculated

Biogen NZ Biopharma Limited operates a professional and well-structured website focused on biotechnology and healthcare, specifically targeting New Zealand residents and healthcare professionals. The company emphasizes innovation in neurology, neuropsychiatry, specialized immunology, and rare diseases. The website reflects a mature digital presence with clear navigation, professional design, and integration with global Biogen branding and social media channels. Technically, the site leverages Adobe Experience Manager CMS, modern JavaScript libraries, and cookie consent management, indicating a solid digital infrastructure. Security posture is good with HTTPS enforced and cookie consent mechanisms, though explicit security policies and incident response contacts are absent. WHOIS data is unavailable, which raises some concerns about domain transparency but does not detract from the overall legitimacy given the strong brand consistency and external references. Overall, the website scores well in content quality, technical implementation, security, privacy compliance, and business credibility, making it a trustworthy and professional corporate site.

Scanned

NIS2 and GDPR posture

GDPR outside view
83/ 100 · Low
Checks completed
7of 7

NIS2 Art. 21(2)

  1. (a) Risk analysis and security policies: Not visible from outside
  2. (b) Incident handling: One indicator
  3. (c) Business continuity, backups and crisis management: Not visible from outside
  4. (d) Supply chain security: Not visible from outside
  5. (e) Secure acquisition, development and maintenance, including vulnerability handling: Partly checked
  6. (f) Assessing the effectiveness of security measures: Not visible from outside
  7. (g) Cyber hygiene and security training: Not visible from outside
  8. (h) Cryptography and encryption: Partly checked
  9. (i) HR security, access control and asset management: One indicator
  10. (j) Multi-factor authentication and secured communications: Not visible from outside

This scan rated NIS2 with an earlier keyword method that is no longer shown; rescan for the per-article view. Risk management, continuity, supply chain, training, MFA, management oversight (Art. 20) and incident reporting (Art. 23) need internal evidence, and Guard cannot tell whether NIS2 applies to this organisation.

GDPR is indicative only, based on publicly visible signals: Articles 7, 12, 13 and 32 of Regulation (EU) 2016/679 and Article 5(3) of the ePrivacy Directive. Not a certification or legal assessment.

Priority findings

2 findings rated critical or high. Fix these first.

  1. Email security

    SPF, DKIM and DMARC stop others sending email that looks like it comes from your domain, a common route to phishing and invoice fraud.

    • Critical

      No email authentication configured

      Domain is vulnerable to email spoofing

      What to do: Implement SPF, DKIM, and DMARC immediately

  2. SSL/TLS

    TLS encrypts the connection and proves the site is really yours. Weak or expiring certificates trigger browser warnings and put traffic at risk.

    • High

      Weak Protocols Supported

      Server supports weak protocols: TLSv1.1

      What to do: Disable TLS 1.0, TLS 1.1, and all SSL versions

      • CWE-327
      • OWASP A04:2025
      • ASVS V12.1.1

Need hands-on remediation? Email guard@offseq.com

Keep watching biogen.co.nz

This scan found 19 issues across 6 checks. Monitoring re-runs those checks daily, emails you when something material changes and records each fix, so you can show progress.

Daily monitoring

Recommended

€25per month

  • TLS certificates and expiry
  • DNS records
  • SPF, DKIM and DMARC
  • Security headers
  • GDPR and NIS2 posture
  • Exposed services
  • Third-party trackers
  • Security score drift

Email alerts on material changes and an exportable JSON history of every change.

Billed monthly to your card. Cancel anytime. The full timeline opens with your unlock code.

Full report

€39.90one-time

  • The complete analysis as a PDF you can cite
  • Email delivery with an unlock code
  • Lifetime access to this report

Prices incl. 21% VAT. Secure checkout by Mollie; sold by SEQ SIA, Latvia.

Results by check

Each check with its score, findings and the evidence it collected.

How this score is calculated

The security score runs 0–100, higher is better. It is the plain average of the security checks that completed in this scan, each counted equally. A check that could not run is left out: it counts neither as a pass nor as a fail.

Counted in this score

SSL/TLS
72
Security headers
95
Email security
60
DNS health
60
Network security
100
GDPR outside view
83
Average
78

Not counted

  • NIS2 outside view: Re-weights evidence from the TLS, email, DNS, network and hygiene checks, so counting it would count that evidence twice. Shown on its own.
  • OffSeq Observations: An AI reading of the site, useful context but not reproducible evidence. Shown on its own.

Findings that cap the score at 49

Each of these is serious on its own, so while any is present the site cannot rate better than high risk, however good the other checks are.

  • The certificate is not trusted by browsers
  • The website is not served over HTTPS
  • A database, remote desktop, file-sharing or Telnet service is reachable from the internet
  • The page loads a script from a compromised source
  • The domain registration has expired
  • SPF authorises every server to send mail as the domain

Partial scans

When the site blocks Guard or most checks cannot run, the score covers only the checks that ran (usually DNS and email), is capped at 75 and is shown as partial, without a risk level.

Risk levels

  • Critical0–25
  • High26–49
  • Medium50–75
  • Low76–100

Technical appendix

Business context, site observations and technical notes gathered during the scan, and the standards behind each reference.

Business context

Business profile

Biogen is positioned as a leading global biotechnology company with a strong local presence in New Zealand. Its business model centers on research and development of therapies for complex neurological and rare diseases. The website targets healthcare professionals, patients, and potential employees, supporting recruitment and corporate communication. The company maintains a consistent global brand with regional adaptations. The presence of multiple regional Biogen domains indicates a broad partnership ecosystem. The lack of direct contact emails or phone numbers suggests a controlled communication channel via contact forms, typical for large enterprises. The company’s focus on innovation and responsibility aligns with industry trends and regulatory expectations.

Security posture

The website demonstrates a good security posture with HTTPS enforced and cookie consent implemented, reflecting compliance with privacy regulations such as GDPR. However, the absence of published security policies, incident response information, and security headers indicates room for improvement. No vulnerabilities or exposed sensitive data were detected in the HTML content. The use of third-party scripts like Google Tag Manager and Cookiebot is standard but requires ongoing monitoring for security risks. The missing WHOIS data reduces transparency but does not directly impact site security. Overall, the security maturity is moderate to good, with recommendations to enhance transparency and technical security controls.

Recommendations

  1. Publish a dedicated security policy page outlining security practices and compliance.
  2. Provide clear incident response contact information to improve trust and readiness.
  3. Implement additional security headers such as Content-Security-Policy and X-Content-Type-Options.
  4. Regularly audit and update third-party scripts to mitigate potential vulnerabilities.
  5. Enhance accessibility features to meet compliance standards and improve user experience.
Site observations

Automated reading of the public site. Ratings are indicative.

Business

Company
Biogen NZ Biopharma Limited
Description
Biogen is a leading global biotechnology company that pioneers science and drives innovations for complex and devastating diseases. Biogen is advancing a pipeline of potential therapies across neurology, neuropsychiatry, specialised immunology and rare disease and remains acutely focused on its purpose of serving humanity through science while advancing a healthier, more sustainable and equitable world.
Key services
Neurology therapies, Neuropsychiatry therapies, Specialized immunology therapies, Rare disease therapies
Content quality
good
Branding
consistent

Technology

Stack
jQuery 3.6.4, Adobe Helix RUM, Cookiebot, Google Tag Manager
Frameworks
Adobe Experience Manager (AEM)
Performance
moderate
Mobile
good
Accessibility
basic
SEO
good

Security

Observed score
85/100
Good practices seen
  • HTTPS enforced
  • Cookie consent mechanism implemented
  • No exposed sensitive data in HTML

Analytics and tracking

Services
Google Tag Manager, Adobe Helix RUM
Tracking level
moderate
Privacy practices
good

Advertising

Tracking pixels
Cookiebot, Adobe Helix RUM
Marketing tools
Cookiebot
Transparency
basic

Site quality

Design
good
User experience
good
Content relevance
good
Navigation
good
Professionalism
good
Trustworthiness
high

Key observations

  1. Website is fully accessible with no blocking or WAF challenges.
  2. Content is professionally presented and relevant to biotechnology and healthcare.
  3. Strong branding consistency with global Biogen presence.
  4. Cookie consent and privacy policies are implemented and accessible.
  5. No direct company emails or phone numbers found on the homepage; contact is via contact form.
  6. WHOIS data is missing, which reduces transparency on domain ownership.
  7. Use of modern web technologies and Adobe Experience Manager CMS.
  8. Social media presence linked to official Biogen accounts.
  9. No explicit security policy or incident response information published.
Technical notes

Notes

The website is built on Adobe Experience Manager CMS, utilizing modern JavaScript libraries including jQuery 3.6.4 and Adobe Helix RUM for performance monitoring. Cookiebot manages cookie consent, ensuring privacy compliance. The site is mobile-optimized with responsive design and good SEO practices including meta tags and Open Graph data. Performance is moderate, with potential for improvement in loading speed and accessibility. The technical infrastructure is robust for an enterprise healthcare website but could benefit from enhanced security headers and performance tuning. No hosting provider details were identified from the HTML content.
Standards and sources

Reference chips under each finding point to the standard, regulation or specification the finding relates to. They are taken from the official datasets below and mapped conservatively: a finding with no defensible link shows none. NIS2 and GDPR references mark where a finding is relevant evidence, not a compliance verdict. Implementing Regulation (EU) 2024/2690 binds digital infrastructure and digital service providers; for other entities it is the most detailed public reading of the Article 21 measures. WCAG, EN 301 549, European Accessibility Act and Web Accessibility Directive references name the requirement an automated accessibility rule relates to; they are not a conformance verdict.

Retrieved 2026-10-25

Reviews of this site

Share your experience with biogen.co.nz. Every review is verified by email and published after moderation.

Overall rating
Select a rating
4000 characters remaining

We’ll email you to confirm your review and keep your details private.

Community rating

No published reviews yet. Be the first to review biogen.co.nz.

Feedback on this report

Rate this report, add an optional comment, and tell us if you want a security specialist to follow up.

Overall report quality
Select a rating
2000 characters remaining

We only use your feedback to improve Guard reports. Contact details are never shared.